Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Navigating Patients' Chemotherapy Decision Making

      December 20, 2012
      By Lisa Schulmeister, RN, MN, APRN-BC, OCN, FAAN
      Publication
      Article
      Oncology Nursing NewsDecember 2012
      Volume 6
      Issue 8

      Patients considering chemotherapy treatment need to understand the risks and benefits of treatment in order to make an informed decision to undergo-or forgo-treatment.

      Lisa Schulmeister, RN, MN, APRN-BC, OCN®, FAAN

      Editor-in-Chief OncLive Nursing

      Oncology Nursing Consultant, Adjunct Assistant Professor of Nursing Louisiana State Health Sciences Center in New Orleans, Louisiana

      Patients considering chemotherapy treatment need to understand the risks and benefits of treatment in order to make an informed decision to undergo—or forgo—treatment. This decision is fairly easy to make when the treatment intent is cure, and evidence exists that the treatment is, in fact, curative. The decision to not receive chemotherapy is much more difficult to make.

      There is a fine line between hope and despair, and what is said is sometimes not heard. We have no crystal ball to tell us what the future holds for a particular patient, so we have to rely on aggregated data in our discussions about prognosis and possible treatment outcomes. Clinicians understandably tend to move quickly from talking about a poor prognosis and no chance of cure, to talking about doing something, such as palliative chemotherapy, rather than doing nothing at all. However, as we all know, there are instances where forgoing chemotherapy treatment would have been a better decision in terms of a patient’s quality of life, and even life expectancy, as sometimes treatment-related deaths do occur.

      Depending on the patient’s perspective, treatment data can be taken any number of ways. Some patients believe that they are going to be in the 10% that respond to treatment and not the 90% who do not respond. Conversely, there are patients who are told that the likelihood of experiencing a certain side effect is low and consequently anticipate that it will occur. It’s partly the “cup is either half empty or half full” perspective and partly how well the information was conveyed in the first place.

      Realistic Expectations

      In a national population cohort study of 1193 patients with metastatic lung or colorectal cancer, researchers found that 69% of the patients with lung cancer and 81% of those with colorectal cancer who were alive 4 months after diagnosis and had opted to receive chemotherapy had inaccurate expectations about the curative potential of the chemotherapy they received.1 Prior studies had found that only a minority of patients believed that palliative chemotherapy would be curative; however, in the prior studies, patients were asked only if the goal of their treatment was cure or palliation.

      In this recently published study, patients were asked how likely they thought it was that chemotherapy would cure them, and most thought that a cure was possible. After accounting for the effect of other factors, including education and income, nonwhite patients were at higher risk for having inaccurate beliefs about chemotherapy, and paradoxically, patients who reported higher scores for physician communication were at higher risk for having inaccurate chemotherapy expectations. It may be the messenger, and not the message, that patients are hearing.

      Communicating Effectively

      The study findings raise the questions of how well are we providing information on treatment intent so that patients can make informed decisions about chemotherapy treatment, and how are patients receiving and interpreting the information we provide? In addition, since most of the patients were not clear on the intent of treatment, what is the possible impact of this misunderstanding on initiating end-of-life planning and care?

      Although treatment intent is usually verbally communicated to a patient, and also often is stated on chemotherapy consent forms, data suggest that patients with advanced cancer may not understand that the chemotherapy is unlikely to be curative. I’m not suggesting that we dash all hopes of disease control or a longer life, but discussions with patients need to be clear about treatment intent. Patient navigators and nurses who provide navigation assistance may be able to improve patients’ understanding of treatment intent and guide patients to timely and appropriate care, such as earlier discussions of end-of-life wishes and earlier referral for palliative care.

      Reference

      1. Weeks JC, Catalono PJ, Cronin A, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616-1625.

      Articles in this issue

      A Surgeon's Perspective on GI Cancer Navigation
      A Life Redirected: Pursuing a Nursing Career After Osteosarcoma
      The Benefits of Genetic Testing for Cancer Survivors
      Navigating Patients' Chemotherapy Decision Making
      Sexual Health Considerations in Cancer Treatment and Survivorship
      Helping Prostate Cancer Patients to Make Informed Treatment Decisions

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman with her hair in a ponytail in front of a light blue background
      Image of a woman with gray hair on a light blue background
      Photo of a man wearing scrubs in front of a blue background
      Related Content

      Graphic of myeloma cells

      Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden

      Bridget Hoyt
      June 25th 2025
      Article

      Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.


      Magazine page with Rx Road Map for Durvalumab for Non-Small Cell Lung Cancer

      Rx Road Map: Durvalumab for Non-Small Cell Lung Cancer

      Stacey Hield, BSN, RN, OCN
      June 19th 2025
      Article

      Read Stacey Hield, BSN, RN, OCN's recommendations for the best use of durvalumab in non–small cell lung cancer.


      Photo of two women smiling with their arms around each other, one with a headwrap

      No One Should Face Cancer Alone: The Power of Community in Cancer Care

      Marissa Fors LCSW, OSW-C, CCM
      June 18th 2025
      Article

      Ask patients, "Who's in your corner?"


      Photo of a nurse recording data on a computer and tablet

      The Evolving Role of the Oncology Nurse in Clinical Trials

      Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN
      June 14th 2025
      Article

      Oncology nurses are paramount to the treatment success of patients, especially through their work on clinical trials.


      Photo of an APP talking to and empowering a patient

      Case Study: Bridging the Gap for Patients With Metastatic CRC

      Randi Kihnel, MSN, APRN, ACCNS-AG
      June 13th 2025
      Article

      Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.


      PDF of Rx Road Map for subcutaneous daratumumab in multiple myeloma

      Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma

      Sylwia Zielinska, RN
      Published: May 7th 2025 | Updated: June 5th 2025
      Article

      A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.

      Related Content

      Graphic of myeloma cells

      Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden

      Bridget Hoyt
      June 25th 2025
      Article

      Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.


      Magazine page with Rx Road Map for Durvalumab for Non-Small Cell Lung Cancer

      Rx Road Map: Durvalumab for Non-Small Cell Lung Cancer

      Stacey Hield, BSN, RN, OCN
      June 19th 2025
      Article

      Read Stacey Hield, BSN, RN, OCN's recommendations for the best use of durvalumab in non–small cell lung cancer.


      Photo of two women smiling with their arms around each other, one with a headwrap

      No One Should Face Cancer Alone: The Power of Community in Cancer Care

      Marissa Fors LCSW, OSW-C, CCM
      June 18th 2025
      Article

      Ask patients, "Who's in your corner?"


      Photo of a nurse recording data on a computer and tablet

      The Evolving Role of the Oncology Nurse in Clinical Trials

      Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN
      June 14th 2025
      Article

      Oncology nurses are paramount to the treatment success of patients, especially through their work on clinical trials.


      Photo of an APP talking to and empowering a patient

      Case Study: Bridging the Gap for Patients With Metastatic CRC

      Randi Kihnel, MSN, APRN, ACCNS-AG
      June 13th 2025
      Article

      Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.


      PDF of Rx Road Map for subcutaneous daratumumab in multiple myeloma

      Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma

      Sylwia Zielinska, RN
      Published: May 7th 2025 | Updated: June 5th 2025
      Article

      A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.

      Latest Conference Coverage

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      Understanding How On-Target and Off-Target ADC Toxicities Work

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.